Jaguar Health Inc (JAGX) Stock Price, Quote & News

Company Profile

Jaguar Health, Inc., a commercial-stage pharmaceuticals company, focuses on developing plant-based prescription medicines for people and animals with gastrointestinal distress. It operates through two segments, Animal Health and Human Health. The company focuses on developing and commercializing prescription and non-prescription products for companion and production animals; and human products. Its lead prescription drug is Mytesi, an anti-secretory antidiarrheal drug for the symptomatic relief...

Industry: Biotechnology

Sector: Healthcare

Phone: 415 371 8300

Website: jaguar.health

Address:

200 Pine Street, Suite 400, San Francisco, United States

ExploringTrades Aug. 4 at 3:30 PM

Ticker NEXR has barely 550,000 shares outstanding. The only comparable ticker was VEEE and that one ran from 4.10$ to over 51$. NEXR released news on Aug 3rd and is shifting heavily into the AI sector. NEXR has only about 700 watchers on Stocktwits. Took a big position looking to profit massively very soon. $JAGX $HCTI $ALZN $BBAI su

1 · Reply

TwinTurboBul161 Aug. 4 at 9:33 AM

$APLD $JAGX $HCTI On6

0 · Reply

Bunster Aug. 4 at 2:37 AM

$JAGX wow just wow girls

0 · Reply

Gluteshevaa Aug. 4 at 1:45 AM

$JAGX how is this still listed. Lisa, take this private. This is embarrassing

0 · Reply

MarketManStockWizzard Aug. 4 at 12:37 AM

$JAGX There are 889.28 preferred Q shares given to John M Fife in exchange for outstanding debt. The Q series will now be given a 50,000 to 1 exchange rate. That means at current share price of $1.00 the Q series would take $44,464,000 worth of equity that simply wipes out retail investors.

0 · Reply

ExploringTrades Aug. 3 at 10:38 PM

ave you seen the Ebola outbreak news this weekend?? 🤯 Make sure to put VRAX onto your watchlist 💎 Ticker VRAX is one of the tiniest float bio-techs that great cash position and Peptides against Ebola! I accumulated a huge amount of shares because of the recent Ebola outbreak. Numbers are rising concerningly fast. The right PR and it could see a big squeeze like the last time we saw an outbreak! $JAGX ::

0 · Reply

MarketManStockWizzard Aug. 3 at 9:52 PM

$JAGX the shares are converted. You need to call your broker to do a audit on your account and tell them to expedite your O series holdings.

1 · Reply

Bunster Aug. 3 at 8:29 PM

$JAGX they had a divident converted the shares june 25 BUT LISA ELCO AND WHOEVER DONT SEEM TO WANT TO DISTRIBUTE THE SHARES WHY IS THAT???

0 · Reply

Ginger77 Aug. 3 at 2:06 AM

$JAGX when is jagx going to have a dividend. Why not everything else has failed.lets put a trump tariff on the costumers and send it to the shareholders.

0 · Reply

MarketManStockWizzard Aug. 2 at 11:19 PM

$JAGX @Bigwinner75 the illistration is showing variable prices based on what the share price would be during time of preferred Q conversion. If the share price is $2.50 then there would be 8,892,800 shares, if its $0.50 then there would be 44,464,000 shares. This issuance is in addition to the 45,000,000 share ATM/ELOC With C/M that was filed last Friday 7/24/2026. We are looking at close to 90,000,000 shares being sold per recent Jaguar Health Inc. Sec.gov filings.

1 · Reply

Jaguar Health Proxy statement: Proxy filing

2026-07-28T13:15:30.000Z - 7 days ago

Jaguar Health announces findings from surveys of dog owners, vet oncologists

Jul 28, 2026, 9:00 AM EDT - 7 days ago

Jaguar Health Reports Positive Consumer and Veterinary Market Research Findings Supporting Commercial Opportunity for Neonorm Dog

Jul 24, 2026, 8:00 AM EDT - 11 days ago

Jaguar Health Registration statement: Registration filing

Jul 24, 2026, 8:00 AM EDT - 11 days ago

Jaguar Health Proxy statement: Proxy filing

2026-07-22T13:10:17.000Z - 13 days ago

Jaguar Health announces additional infant to receive crofelemer powder

Jul 22, 2026, 9:00 AM EDT - 13 days ago

Additional Infant Patient to Receive Jaguar Health's Crofelemer for Compassionate Use for Treatment of Intestinal Failure (IF) Due to Microvillus Inclusion Disease (MVID)

Jul 16, 2026, 8:00 AM EDT - 19 days ago

Jaguar Health Registration statement: Registration filing

Jul 16, 2026, 8:00 AM EDT - 19 days ago

Jaguar Health Registration statement: Registration filing

2026-07-16T10:06:17.000Z - 19 days ago

Jaguar Health files to sell 5.52M shares of voting common stock for holders

2026-07-16T10:06:00.000Z - 19 days ago

Jaguar Health files to sell 40.8M shares of voting common stock for holders

2026-06-30T13:15:53.000Z - 5 weeks ago

Jaguar Health provides recap of presentations of crofelemer at ESPGHAN

Jun 30, 2026, 9:00 AM EDT - 5 weeks ago

Presentation at ESPGHAN 2026 Describes Additional Groundbreaking Results of Evaluation of Jaguar Health's Crofelemer as Adjunctive Oral Therapy for the Treatment of Pediatric Intestinal Failure (IF)

2026-06-25T13:10:22.000Z - 5 weeks ago

Jaguar Health announces conversion of Series O convertible preferred stock

Jun 25, 2026, 9:00 AM EDT - 5 weeks ago

Jaguar Health Announces Conversion of Series O Convertible Preferred Stock Issued as Recent One-time Stock Dividend

Jun 24, 2026, 1:00 PM EDT - 5 weeks ago

Jaguar Health Transcript: Life Sciences Virtual Investor Forum

2026-06-23T16:23:11.000Z - 5 weeks ago

Jaguar Health completes submission of NADA to U.S. FDA for crofelemer

Jun 23, 2026, 9:00 AM EDT - 6 weeks ago

Jaguar Health Completes Submission of New Animal Drug Application for Full FDA Approval of Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

2026-06-22T13:29:23.000Z - 6 weeks ago

Jaguar Health initiates process to explore, review strategic alternatives

Jun 22, 2026, 9:00 AM EDT - 6 weeks ago

Jaguar Health Announces Plan to Explore Strategic Alternatives Aligned with Targeted NDA Filing for Rare Disease Intestinal Failure Program

2026-06-18T13:26:22.000Z - 6 weeks ago

Magdalena Biosciences announces results from preclinical study of coca

Jun 18, 2026, 9:00 AM EDT - 6 weeks ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Announces Positive Results of Preclinical Study of Coca for Weight Gain Prevention

Jun 12, 2026, 9:00 AM EDT - 7 weeks ago

Jaguar Health Presenting June 24, 2026 at the Life Sciences Virtual Investor Forum to Provide Updates on Company's Crofelemer Development Program for Rare Intestinal Failure Diseases

Jun 10, 2026, 12:35 PM EDT - 7 weeks ago

Jaguar Health Transcript: Emerging Growth Conference 93

Jun 8, 2026, 4:15 PM EDT - 2 months ago

Jaguar Health Reports Approval of All Proposals at 2026 Annual Meeting of Stockholders

May 29, 2026, 8:00 AM EDT - 2 months ago

Jaguar Health Proxy statement: Proxy filing

2026-05-28T17:08:58.000Z - 2 months ago

Jaguar Health says research in ethnobotanical medicine helps advance crofelemer

May 28, 2026, 10:00 AM EDT - 2 months ago

Jaguar Health Research in Ethnobotanical Medicine Helps Advance Crofelemer Development for Genetically Defined Rare Congenital Gastrointestinal Disorders

May 28, 2026, 10:00 AM EDT - 2 months ago

Jaguar Health Transcript: Lytham Partners Spring 2026 Investor Conference

2026-05-27T15:43:15.000Z - 2 months ago

Jaguar Health regains compliance with Nasdaq Listing Rule

May 27, 2026, 9:00 AM EDT - 2 months ago

Jaguar Health Compliant with Nasdaq Bid Price Rule

May 26, 2026, 8:30 AM EDT - 2 months ago

Jaguar Health Earnings Call Transcript: Q1 2026

May 26, 2026, 8:30 AM EDT - 2 months ago

Jaguar Health Quarterly report: Q1 2026

May 26, 2026, 8:30 AM EDT - 2 months ago

Jaguar Health Earnings release: Q1 2026

May 22, 2026, 7:00 AM EDT - 2 months ago

Jaguar Health Slides: Corporate presentation

2026-05-20T20:50:10.000Z - 2 months ago

Jaguar Health reports Q1 EPS ($13.60) vs. ($584.45) last year

May 20, 2026, 4:40 PM EDT - 2 months ago

Jaguar Health Reports First Quarter 2026 Financials

May 20, 2026, 9:00 AM EDT - 2 months ago

Jaguar Health to Hold Investor Webcast May 26 Regarding Q1 2026 Financials & Corporate Updates; Jaguar CEO Lisa Conte Presenting May 28 at Lytham Partners Spring 2026 Investor Conference

2026-05-19T13:27:49.000Z - 2 months ago

Jaguar says first patient from pediatric MVID entered active treatment

May 19, 2026, 9:00 AM EDT - 2 months ago

Jaguar Health Announces Active Treatment Only Continuation of Pivotal Multicenter Clinical Trial in Pediatric Patients with Microvillus Inclusion Disease (MVID) to Support a New Drug Application (NDA) for Liquid Oral Crofelemer

2026-05-08T15:09:27.000Z - 3 months ago

Jaguar Health granted extension to comply with Nasdaq bid price rule

May 8, 2026, 9:00 AM EDT - 3 months ago

Jaguar Health Regains Compliance with Nasdaq's Publicly Held Shares Requirement and Receives Additional Extension, Until May 18, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule

2026-05-07T04:48:16.000Z - 3 months ago

Jaguar Health’s Napo held preliminary discussion with FDA over crofelemer

May 6, 2026, 9:00 AM EDT - 3 months ago

Jaguar Health Announces Preliminary Discussion with FDA to Evaluate Breakthrough Therapy Designation for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

May 6, 2026, 8:00 AM EDT - 3 months ago

Jaguar Health Proxy statement: Proxy filing

2026-05-04T13:09:38.000Z - 3 months ago

Jaguar Health announces planned launch of Neonorm Dog

May 4, 2026, 8:30 AM EDT - 3 months ago

Jaguar Health Expands Neonorm Franchise with Introduction of Neonorm Dog for Companion Animal Gut Health

Apr 30, 2026, 8:00 AM EDT - 3 months ago

Jaguar Health Proxy statement: Proxy filing

2026-04-29T14:15:11.000Z - 3 months ago

Jaguar Health announces results from trial of crofelemer

Apr 29, 2026, 8:30 AM EDT - 3 months ago

Jaguar Health Announces Statistically Significant Results from Effectiveness Trial of Crofelemer (FDA Approved Canalevia-CA1) for Treatment of Chemotherapy-Induced Diarrhea in Dogs

2026-04-27T13:41:07.000Z - 3 months ago

Jaguar Health granted extension to demonstrate compliance with Nasdaq bid rule

Apr 27, 2026, 9:00 AM EDT - 3 months ago

Jaguar Health Granted Extension Until May 15, 2026, to Demonstrate Compliance with Nasdaq's Bid Price Rule; Company Announces Reverse Stock Split

Apr 24, 2026, 8:30 AM EDT - 3 months ago

Jaguar Health Announces Acceptance of two Late-Breaking Abstracts for Liquid Oral Crofelemer Treatment of Intestinal Failure in Pediatric Patients at the European Society for Pediatric Gastroenterology, Hepatology & Nutrition (ESPGHAN)

Apr 20, 2026, 4:15 PM EDT - 3 months ago

Jaguar Health Reports Approval of All Proposals at April 2026 Special Meeting of Stockholders

Apr 20, 2026, 8:00 AM EDT - 3 months ago

Jaguar Health Proxy statement: Proxy filing

Apr 13, 2026, 8:30 AM EDT - 4 months ago

Artificial Intelligence (AI) Platforms Could Enhance Jaguar Health's Development and Anticipated Commercialization of Crofelemer for Rare Disease Intestinal Failure (IF) Programs

Apr 10, 2026, 8:30 AM EDT - 4 months ago

Jaguar Health Earnings Call Transcript: Q4 2025

Apr 10, 2026, 8:30 AM EDT - 4 months ago

Jaguar Health Earnings release: Q4 2025

Apr 10, 2026, 8:30 AM EDT - 4 months ago

Jaguar Health Annual report: Q4 2025

Apr 9, 2026, 8:15 PM EDT - 4 months ago

Reminder: Jaguar Health to Host Investor Webcast at 8:30 am Eastern on Friday, April 10, 2026 Regarding Q4 2025 Financials and Company Updates

Apr 8, 2026, 8:30 AM EDT - 4 months ago

Jaguar Health Completes Effectiveness Trial to Support FDA Approved Crofelemer for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Apr 7, 2026, 8:30 AM EDT - 4 months ago

Jaguar Health Reports 2025 Financials

Apr 2, 2026, 9:00 AM EDT - 4 months ago

Jaguar Health Family Company Napo Pharmaceuticals Co-Sponsoring Pediatric Gastroenterology Conference: Elite Ped-GI Congress

Mar 24, 2026, 8:00 AM EDT - 4 months ago

Jaguar Health Proxy statement: Proxy filing

Mar 18, 2026, 9:00 AM EDT - 4 months ago

FDA Feedback Supports Extension Phase for Jaguar Health's Clinical Trial of Crofelemer for Treatment of Microvillus Inclusion Disease (MVID)

Mar 16, 2026, 9:00 AM EDT - 5 months ago

Magdalena Biosciences, a Joint Venture Between Jaguar Health and Filament Health, Initiates Preclinical Study of Coca for Appetite Suppression

Mar 13, 2026, 8:00 AM EDT - 5 months ago

Jaguar Health Proxy statement: Proxy Filing

Mar 12, 2026, 2:00 PM EDT - 5 months ago

Jaguar Health Transcript: Life Sciences Virtual Investor Forum

Mar 11, 2026, 9:00 AM EDT - 5 months ago

Jaguar Health Presenting March 12 at the Life Sciences Virtual Investor Forum to Provide Updates on Near-Term Catalysts

Mar 9, 2026, 9:00 AM EDT - 5 months ago

Jaguar Health Strengthens Company's Balance Sheet by Restructuring and Reducing Royalty and Debt Obligations and Extinguishing Warrants

Mar 3, 2026, 9:00 AM EST - 5 months ago

Jaguar Health Secures an Additional $3 Million Payment from Future Pak for Mytesi and Canalevia-CA1

Mar 2, 2026, 9:00 AM EST - 5 months ago

Reminder: Today, March 2, 2026, is the Record Date for Jaguar Health's Special One-time Stock Dividend

Feb 18, 2026, 9:00 AM EST - 5 months ago

Jaguar Health Announces a Special One-time Stock Dividend

Jan 22, 2026, 9:00 AM EST - 6 months ago

Jaguar Health Highlights Sharp Strategic Focus on Rare Intestinal Failure Diseases Fueled by Non-Dilutive Funds from Closing of License Deal for Mytesi

Jan 15, 2026, 3:30 PM EST - 7 months ago

Jaguar Health Transcript: 2nd Annual Lytham Partners Healthcare Investor Summit

Jan 14, 2026, 9:00 AM EST - 7 months ago

Jaguar Health Presenting January 15 at Lytham Partners Healthcare Investor Summit to Provide Updates on Near-Term Catalysts

Jan 12, 2026, 9:00 AM EST - 7 months ago

Jaguar Health Enters into U.S. License Agreement with Future Pak for Crofelemer, Providing up to $38 Million

Jan 6, 2026, 9:00 AM EST - 7 months ago

Article About Groundbreaking Results from Study of Jaguar Health's Crofelemer for Treatment of Intestinal Failure Featured in United Arab Emirates Healthcare Publication

Jan 2, 2026, 9:00 AM EST - 7 months ago

Jaguar Health Awarded $240,000 FDA Grant in Support of Canalevia-CA1 for Treatment of Chemotherapy-Induced Diarrhea (CID) in Dogs

Dec 15, 2025, 9:00 AM EST - 8 months ago

Jaguar Health Announces Abstract Submission for Preliminary Data from US Investigator-Initiated Trial of Crofelemer in Adult Patients with Short Bowel Syndrome with Intestinal Failure (SBS-IF)

Dec 10, 2025, 3:25 PM EST - 8 months ago

Jaguar Health Transcript: Emerging Growth Conference 88

Dec 10, 2025, 9:00 AM EST - 8 months ago

FDA Approves Renewal of Canalevia-CA1, Jaguar Health's Drug for Chemotherapy-Induced Diarrhea (CID) in Dogs

Dec 9, 2025, 6:00 PM EST - 8 months ago

Jaguar Health Slides: Corporate Presentation

Dec 8, 2025, 4:15 PM EST - 8 months ago

Jaguar Health Reports Approval of All Proposals at December 2025 Special Meeting of Stockholders

Dec 2, 2025, 9:00 AM EST - 8 months ago

Jaguar Health Makes Submission to EMA Regarding EU Approval Pathway for Canalevia for General Diarrhea in Dogs Based on Data from Completed Study

Nov 24, 2025, 9:00 AM EST - 9 months ago

Jaguar Health Secures New Patent for Crofelemer in Short Bowel Syndrome, Strengthening Global IP Position Ahead of Additional Clinical Milestones

Nov 20, 2025, 9:00 AM EST - 9 months ago

In Support of Possible Expedited Approval Pathway for Crofelemer for Treatment of Microvillus Inclusion Disease (MVID), Jaguar Health Submits Amended Protocol to FDA for Ongoing Placebo-Controlled Clinical Trial

Nov 17, 2025, 8:30 AM EST - 9 months ago

Jaguar Health Earnings Call Transcript: Q3 2025

Nov 17, 2025, 8:30 AM EST - 9 months ago

Jaguar Health Earnings release: Q3 2025

Nov 17, 2025, 8:30 AM EST - 9 months ago

Jaguar Health Quarterly report: Q3 2025

Nov 17, 2025, 8:00 AM EST - 9 months ago

Jaguar Health Reports Third Quarter 2025 Financials: Net Q3 2025 Revenue Up Approximately 4% Versus Net Q2 2025 Revenue

Nov 14, 2025, 9:00 AM EST - 9 months ago

Jaguar Health to Hold Investor Webcast Monday, November 17 at 8:30 AM Eastern Regarding Q3 2025 Financials & Corporate Updates

Nov 13, 2025, 9:00 AM EST - 9 months ago

Jaguar Health Provides Recap of November 8, 2025 Presentation on Groundbreaking Results of Proof-of-Concept Study of Crofelemer for Treatment of Pediatric Intestinal Failure at NASPGHAN Annual Meeting

Nov 10, 2025, 7:00 AM EST - 9 months ago

Jaguar Health Proxy statement: Proxy Filing

Nov 6, 2025, 9:00 AM EST - 9 months ago

REMINDER: Initial Groundbreaking Results of Proof-of-Concept Study of Jaguar Health's Crofelemer for Treatment of Pediatric Intestinal Failure to be Presented November 8, 2025 at North American Society for Pediatric Gastroenterology, Hepatology and Nutrition (NASPGHAN) Annual Meeting

Oct 28, 2025, 8:00 AM EDT - 10 months ago

Jaguar Health Proxy statement: Proxy Filing

Oct 24, 2025, 4:15 PM EDT - 10 months ago

Jaguar Health Announces New Employee Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Oct 6, 2025, 9:00 AM EDT - 10 months ago

Jaguar Health Completes Meeting with FDA for Advice on Development Pathways to Advance Ongoing Crofelemer Trial for Potential Approval for Treatment of Pediatric Indication Microvillus Inclusion Disease (MVID)

ExploringTrades Aug. 4 at 3:30 PM

1 · Reply

TwinTurboBul161 Aug. 4 at 9:33 AM

$APLD $JAGX $HCTI On6

0 · Reply

Bunster Aug. 4 at 2:37 AM

$JAGX wow just wow girls

0 · Reply

Gluteshevaa Aug. 4 at 1:45 AM

$JAGX how is this still listed. Lisa, take this private. This is embarrassing

0 · Reply

MarketManStockWizzard Aug. 4 at 12:37 AM

0 · Reply

ExploringTrades Aug. 3 at 10:38 PM

0 · Reply

MarketManStockWizzard Aug. 3 at 9:52 PM

$JAGX the shares are converted. You need to call your broker to do a audit on your account and tell them to expedite your O series holdings.

1 · Reply

Bunster Aug. 3 at 8:29 PM

$JAGX they had a divident converted the shares june 25 BUT LISA ELCO AND WHOEVER DONT SEEM TO WANT TO DISTRIBUTE THE SHARES WHY IS THAT???

0 · Reply

Ginger77 Aug. 3 at 2:06 AM

$JAGX when is jagx going to have a dividend. Why not everything else has failed.lets put a trump tariff on the costumers and send it to the shareholders.

0 · Reply

MarketManStockWizzard Aug. 2 at 11:19 PM

1 · Reply

Dolceanna100 Aug. 2 at 4:27 PM

$JAGX Instead, ask yourself how much the Nasdaq Composite Index was worth in 2015. And why jagx Is down -100% from 2015...

0 · Reply

Bigwinner75 Aug. 2 at 4:58 AM

$JAGX I am bored. If you talk about dilution. America itself is the biggest scam. Ask yourself how much is 100 dollars now compare to 2 years ago , 5 years ago 15 years ago.

0 · Reply

Bigwinner75 Aug. 2 at 4:43 AM

$JAGX when this stock was at 400 dollars pre split. I was the biggest bear here. People were cursing me telling me to fuck off. Seriously I want people to make money this round

0 · Reply

Bigwinner75 Aug. 2 at 4:40 AM

$JAGX people deserve to make some money back. I know it has been tough. I hope everyone can make their money back.

0 · Reply

Bigwinner75 Aug. 2 at 4:38 AM

$JAGX Thank you for the gift My lovely female CEO. I love you

0 · Reply

Bigwinner75 Aug. 2 at 4:37 AM

$JAGX even 40s. That’s when I will double down

0 · Reply

Bigwinner75 Aug. 2 at 4:35 AM

$JAGX but of course Johnny is using these warrants to short. So he is making money in the round trip. I can’t say bad things about him. He want a profit too. We all are

0 · Reply

Bigwinner75 Aug. 2 at 4:33 AM

$JAGX excuse me. Very stupid question as it is. 34 m by 20 m share. Each share going around $1.7

0 · Reply

MarketManStockWizzard Jul. 31 at 7:16 PM

$JAGX I'm saying 20M shares, but that's with a $1.00 hypothetical exchange. Jagx is showing 44m shares @ $0.50 per share.. all this in addition to the 40m atm/eloc offering that was effective as of Friday. Do your homework... lotsa dilution to steer clear of here! See filing attached, https://www.sec.gov/ix?doc=/Archives/edgar/data/0001585608/000119312526316119/d165765dpre14a.htm

0 · Reply

Bunster Jul. 31 at 6:04 PM

$JAGX WHERES ANDY

0 · Reply

MarketManStockWizzard Jul. 31 at 5:23 PM

$JAGX Read new PRE14 1. Approving, for purposes of Nasdaq Listing Rule 5635(d), the issuance of shares of our Common Stock issuable upon exchange of shares of our Series Q Perpetual Preferred Stock, par value $0.0001 per share (the “Series Q Preferred Stock”) issued to John M. Fife 20M shares of dilution to repay the $34M debt.

0 · Reply

MarketManStockWizzard Jul. 31 at 5:14 PM

$JAGX Too bad these daytraders that were gonna learn me a thing or two, are now permanent guests. With all that playing around with the ask, its triggered a new all time low. We should soon see the $0.80's

0 · Reply

Market Cap	603,000.00
Revenue (ttm)	11.51M
Net Income (ttm)	-53.43M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	-464.21%
Debt to Equity Ratio	-0.70

Volume	101,600
Avg Vol	91,506
Day's Range	N/A - N/A
Shares Out	603,000.00
Stochastic %K	20%
Beta	-0.11
Analysts	Strong Buy
Price Target	$16.00